About
Medial EarlySign’s AI-driven machine learning solutions empower healthcare stakeholders to keep patients healthier for extended periods. The company’s advanced models derive actionable clinical insights from massive datasets, helping improve patient outcomes, optimize diagnostics, and enhance medication management. Medial EarlySign's purpose-built development environment ensures precision decision-making, supported by peer-reviewed studies published by leading healthcare organizations worldwide.
EarlySign helps clients identify people at high risk for conditions such as non-small cell lung cancer (NSCLC), lower GI disorders and cancers, prediabetic progression to diabetes, downstream diabetic complications, risk for flu and its complications, chronic kidney disease (CKD), COVID-19, and more.
The company was named a cool vendor in "Cool Vendors in AI for Healthcare, 2017" by the Gartner Research Group and was a winner of the CMS AI Health Outcomes Challenge.
Funding history · 2 rounds · $50.0M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the operational status of Medial EarlySign as of October 2025?
- As of October 2025, Medial EarlySign ceased to operate and is currently inactive.
- When was Medial EarlySign founded and what was its initial focus?
- Medial EarlySign was founded in January 2009. The company focuses on early detection of life-threatening conditions using AI-driven machine learning solutions.
- What was Medial EarlySign's total funding raised and from which major investors?
- Medial EarlySign raised a total of $50,000,000. Key investors include Horizons Ventures, Li Ka-shing, aMoon Fund, and Viola Ventures. For a full financing history, refer to startupim.
- When did Medial EarlySign complete its Series B funding round and what was the amount?
- Medial EarlySign completed its Series B funding round in March 2018, raising $30,000,000.
- Which major pharmaceutical company did Medial EarlySign collaborate with for lung cancer detection?
- In July 2022, Medial EarlySign announced a strategic collaboration agreement with Roche on an AI solution for the early detection of lung cancer.
- What recognition did Medial EarlySign receive from Gartner Research Group in 2017?
- Medial EarlySign was named a 'Cool Vendor' in 'Cool Vendors in AI for Healthcare, 2017' by the Gartner Research Group.
- Did Medial EarlySign partner with an Israeli HMO for COVID-19 risk detection?
- Yes, in April 2020, Medial EarlySign partnered with Israeli HMO Maccabi to launch an AI algorithm to detect high-risk COVID-19 cases.
- Which US healthcare provider partnered with Medial EarlySign for AI algorithms to spot chronic disease?
- In July 2019, Geisinger partnered with Medial EarlySign for AI algorithms focused on population health and precision medicine to identify chronic diseases.
- How many employees did Medial EarlySign have?
- Medial EarlySign had 12 employees, falling within the 11-50 employee bucket.